How to buy Genfit S-A stock

Genfit S.A is a biotechnology business based in the US. Genfit S-A shares (GNFT) are listed on the NASDAQ and all prices are listed in US Dollars.

Genfit S-A share price

Use our graph to track the performance of GNFT stocks over time.

Genfit S-A shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$3.63 - $22.20
50-day moving average	$4.59
200-day moving average	$4.88
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Genfit S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Genfit S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Genfit S.A by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genfit S-A financials

Revenue TTM	$7.8 million
Gross profit TTM	$7.8 million
Return on assets TTM	-19.06%
Return on equity TTM	-298.13%
Profit margin	0%
Book value	$0.95
Market capitalisation	$204.6 million

TTM: trailing 12 months

Shorting Genfit S-A shares

There are currently 13,427 Genfit S-A shares held short by investors – that's known as Genfit S-A's "short interest". This figure is 50% up from 8,951 last month.

There are a few different ways that this level of interest in shorting Genfit S-A shares can be evaluated.

Genfit S-A's "short interest ratio" (SIR)

Genfit S-A's "short interest ratio" (SIR) is the quantity of Genfit S-A shares currently shorted divided by the average quantity of Genfit S-A shares traded daily (recently around 31225.581395349). Genfit S-A's SIR currently stands at 0.43. In other words for every 100,000 Genfit S-A shares traded daily on the market, roughly 430 shares are currently held short.

However Genfit S-A's short interest can also be evaluated against the total number of Genfit S-A shares, or, against the total number of tradable Genfit S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genfit S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Genfit S-A shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genfit S-A shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genfit S-A.

Find out more about how you can short Genfit S-A stock.

Genfit S-A share dividends

We're not expecting Genfit S-A to pay a dividend over the next 12 months.

Genfit S-A share price volatility

Over the last 12 months, Genfit S-A's shares have ranged in value from as little as $3.63 up to $22.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit S-A's is 1.165. This would suggest that Genfit S-A's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Genfit S-A overview

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France. .

Frequently asked questions

What percentage of Genfit S-A is owned by institutions?
Currently 0.727% of Genfit S-A shares are held by institutions. When does the fiscal year end for Genfit S-A?
Genfit S-A's fiscal year ends in December. Where is Genfit S-A based?
Genfit S-A's address is: Parc EurasantE, Loos, France, 59120 What is Genfit S-A's ISIN number?
Genfit S-A's international securities identification number is: US3722791098 What is Genfit S-A's CUSIP number?
Genfit S-A's Committee on Uniform Securities Identification Procedures number is: 372279109